公开(公告)号：EP3150577B1

公开(公告)日：2018-08-29

申请号：EP16002350.3

申请日：2012-09-27

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Naganawa, Atsushi ,  Kusumi, Kensuke ,  Otsuki, Kazuhiro ,  Sekiguchi, Tetsuya ,  Kakuuchi, Akito ,  Shinozaki, Koji ,  Yamamoto, Hiroshi ,  Nonaka, Shigeyuki

IPC分类号： C07D205/04 ,  A61K31/397 ,  A61K31/40 ,  A61K31/445 ,  A61K31/4523 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/5377 ,  A61P9/00 ,  A61P9/06 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P11/00 ,  A61P25/00 ,  A61P43/00 ,  C07D207/10 ,  C07D207/12 ,  C07D211/48

CPC分类号： A61K31/445 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4523 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4545 ,  C07D205/04 ,  C07D207/12 ,  C07D207/16 ,  C07D211/48 ,  C07D211/52 ,  C07D401/12 ,  C07D405/12

摘要： The compound represented by the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P 2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P 2 -mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases.

公开(公告)号：EP3150577A1

公开(公告)日：2017-04-05

申请号：EP16002350.3

申请日：2012-09-27

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Naganawa, Atsushi ,  Kusumi, Kensuke ,  Otsuki, Kazuhiro ,  Sekiguchi, Tetsuya ,  Kakuuchi, Akito ,  Shinozaki, Koji ,  Yamamoto, Hiroshi ,  Nonaka, Shigeyuki

IPC分类号： C07D205/04 ,  A61K31/397 ,  A61K31/40 ,  A61K31/445 ,  A61K31/4523 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/5377 ,  A61P9/00 ,  A61P9/06 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P11/00 ,  A61P25/00 ,  A61P43/00 ,  C07D207/10 ,  C07D207/12 ,  C07D211/48

CPC分类号： A61K31/445 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4523 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4545 ,  C07D205/04 ,  C07D207/12 ,  C07D207/16 ,  C07D211/48 ,  C07D211/52 ,  C07D401/12 ,  C07D405/12

摘要： The compound represented by the formula (I-1):

wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P 2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P 2 -mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases.